LENZ Therapeutics, Inc. (LENZ)

NMS – Цена в реальном времени. Валюта: USD

5.04

-0.17 (-3.26%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

5.16

+0.12 (2.38%)

После закрытия: Aug 12, 2026, 4:31 PM EDT

12.08.2026

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

11.08.2026

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.

11.08.2026

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.

11.08.2026

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since launch, tracking to five packs annually VIZZ prescription growth accelerated with launch of telehealth channel in July 2026 Management to host conference call today, August 11, 2026, at 4:30 p.m. EDT SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the second quarter ended June 30, 2026, and recent corporate highlights.

04.08.2026

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights.

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

LENZ Therapeutics, Inc. (LENZ)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

Видео

No Data

Пресс-релизы

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

Видео

No Data

Пресс-релизы

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Search stocks

LENZ Therapeutics, Inc. (LENZ)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

Видео

No Data

Пресс-релизы

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

Видео

No Data

Пресс-релизы

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights